Reversible vascular calcifications associated with hypervitaminosis D.

Vascular calcifications are commonly linked to chronic conditions like atherosclerosis or chronic kidney disease. However, the role of vitamin D excess in causing such calcifications remains unclear. Prior research has shown that hypercalcemia and hyperphosphatemia can lead to ectopic calcification. Yet, whether these calcifications are reversible in cases of hypervitaminosis D is uncertain. This gap motivated the investigation of a case where vascular calcifications were observed alongside high vitamin D levels. No prior work had resolved whether such calcifications could regress with treatment. Understanding the reversibility of these changes could help in managing patients with vitamin D toxicity. The absence of long-term follow-up in similar cases limits current knowledge. This paper contributes by presenting a unique case with a 12-year follow-up. The findings may guide future diagnostic and therapeutic approaches.

The aim of this case report was to investigate the reversibility of vascular calcifications associated with hypervitaminosis D. The patient presented with symptoms of hypercalcemia and widespread calcifications. The specific problem addressed was whether vascular calcifications could resolve after correcting vitamin D toxicity. The motivation stemmed from the lack of prior evidence on this topic. The patient's medical history included high-dose cholecalciferol treatment, leading to severe hypercalcemia. The study aimed to track the progression and regression of calcifications over time. The 12-year follow-up provided a unique opportunity to assess long-term outcomes. This case could inform clinical management of similar patients.

The study involved a single-patient case report with longitudinal follow-up. Clinical symptoms, lab tests, and imaging were used to monitor the patient's condition. Serum calcium, phosphate, and vitamin D levels were measured regularly. Intravenous saline and furosemide were used to manage hypercalcemia. Prednisone and omeprazole were administered to address hypervitaminosis D. Imaging assessments included X-rays and other modalities to track calcifications. The patient's condition was followed for 12 years post-discharge. The treatment duration lasted approximately six months. The follow-up included repeat lab tests and imaging to assess calcification regression.

The patient's serum calcium levels improved after treatment with intravenous saline and furosemide. Kidney function and consciousness also showed improvement. Prednisone and omeprazole were effective in managing hypervitaminosis D. Over six months, hypercalcemia resolved completely. Imaging showed a significant reduction in vascular calcifications. Gluteal and pelvic calcifications also decreased. Twelve years later, the patient had normal calcium and kidney function. Only minor vascular calcifications remained at the final follow-up.

The authors propose that vascular calcifications can be reversible in cases of hypervitaminosis D. The patient's condition improved with treatment targeting hypercalcemia and vitamin D excess. The findings suggest a direct link between vitamin D toxicity and calcification formation. The resolution of calcifications supports the hypothesis that they were secondary to vitamin D. The 12-year follow-up confirmed the long-term reversibility of these changes. The study highlights the importance of monitoring vitamin D levels in at-risk patients. The results may guide future treatment strategies for similar cases. This case provides the first evidence of reversible vascular calcifications due to hypervitaminosis D.